<DOC>
	<DOCNO>NCT02849951</DOCNO>
	<brief_summary>The purpose study determine whether Phosphatidylcholine ( LT-02 ) add treatment effective safe induction remission ulcerative colitis patient refractory standard treatment mesalamine</brief_summary>
	<brief_title>A Study Investigate Safety Efficacy LT-02 Patients With Mesalamine Refractory Ulcerative Colitis ( UC )</brief_title>
	<detailed_description>A randomized , double-blind , placebo-controlled study ass efficacy safety LT-02 ( delay release phosphatidylcholine granule ; administer orally via 1.6 g BID 12 week ) subject active ulcerative colitis refractory standard dose oral mesalamine therapy . Refractory mesalamine define active disease despite receive least ≥ 2.4g mesalamine ( equivalent dose ) least 8 week without rectal 5-ASA .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Key 1 . Established diagnosis ulcerative colitis ( UC ) , base clinical history , exclusion infectious cause , characteristic endoscopic histologic finding . 2 . Active UC disease confirm endoscopy finding confirm central reader . 3 . A modified Mayo Score 410 , centrally read endoscopy score activity ≥ 2 point . 4 . Mesalamine ( 5ASA ) refractory . 1 . Diagnosis Crohn 's disease , indeterminate colitis , ischemic colitis , radiation colitis , microscopic colitis ( i.e. , collagenous colitis lymphocytic colitis ) , diverticular disease associate colitis , 2 . Toxic megacolon fulminant colitis , 3 . Prior colon resection , 4 . Evidence infectious colitis ( e.g. , pathogenic bacteria Clostridium difficile infection ) screening , 5 . Known celiac disease 6 . Other inflammatory bleed disorder colon intestine , disease may cause diarrhea gastrointestinal bleeding 7 . History presence ischemic heart disease , myocardial infarction , peripheral arterial disease , ischemic stroke , transient ischemic attack , 8 . Subjects know hypersensitivity soy , 9 . Treatment methotrexate , azathioprine , 6mercaptopurine TNFalphaantagonists , vedolizumab certolizumab pegol , tacrolimus , antiintegrin therapy within last 8 week prior screen , 10 . Treatment ( topical systemic ) corticosteroid formulation treatment IBD within last 7 day prior endoscopy , 11 . Treatment investigational drug within last 8 week prior screen ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Colitis</keyword>
	<keyword>Colitis , Ulcerative</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Inflammatory Bowel Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Mesalamine</keyword>
</DOC>